• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.先前存在的对流感病毒血凝素茎的免疫可能会在人体挑战模型中推动对抗体逃逸突变病毒的选择。
Nat Med. 2020 Aug;26(8):1240-1246. doi: 10.1038/s41591-020-0937-x. Epub 2020 Jun 29.
2
Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.血凝素茎部结构域突变不允许在小鼠模型中逃避基于茎部的保护性疫苗诱导的免疫应答。
mBio. 2021 Feb 16;12(1):e03617-20. doi: 10.1128/mBio.03617-20.
3
Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.评估雪貂基于流感病毒血凝素茎的免疫原性。
J Virol. 2014 Mar;88(6):3432-42. doi: 10.1128/JVI.03004-13. Epub 2014 Jan 8.
4
Impact of pre-existing immunity on the induction of functional cross-reactive anti-hemagglutinin stalk antibodies following vaccination with an AS03 adjuvanted pandemic H1N1 vaccine.AS03 佐剂季节性流感 H1N1 疫苗接种后,预先存在的免疫对功能性交叉反应性抗血凝素茎抗体诱导的影响。
Vaccine. 2018 Apr 12;36(16):2213-2219. doi: 10.1016/j.vaccine.2018.02.022. Epub 2018 Mar 13.
5
Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for Protection in a Serum Transfer Mouse Challenge Model.人血清中流感病毒血凝素茎特异性抗体是血清转移小鼠攻毒模型中保护作用的替代标志物。
mBio. 2017 Sep 19;8(5):e01463-17. doi: 10.1128/mBio.01463-17.
6
Assessing the Protective Potential of H1N1 Influenza Virus Hemagglutinin Head and Stalk Antibodies in Humans.评估 H1N1 流感病毒血凝素头部和茎部抗体在人体中的保护潜力。
J Virol. 2019 Apr 3;93(8). doi: 10.1128/JVI.02134-18. Print 2019 Apr 15.
7
1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.1976 年和 2009 年 H1N1 流感病毒疫苗可增强人体抗血凝素茎抗体。
J Infect Dis. 2013 Jan 1;207(1):98-105. doi: 10.1093/infdis/jis652. Epub 2012 Oct 18.
8
Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus.球状头部展示的保守流感H1血凝素茎部表位赋予针对异源H1N1病毒的保护作用。
PLoS One. 2016 Apr 18;11(4):e0153579. doi: 10.1371/journal.pone.0153579. eCollection 2016.
9
Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.非中和性 IgA 抗体在针对多种血凝素亚型流感 A 病毒的交叉保护免疫中的潜在作用。
J Virol. 2020 Jun 1;94(12). doi: 10.1128/JVI.00408-20.
10
Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.新型 H3 特异性广谱中和单克隆抗体的鉴定 该抗体靶向血凝素球状头部,来源于一位具有广泛血清学反应性的流感病毒免疫供者
J Virol. 2020 Feb 28;94(6). doi: 10.1128/JVI.01035-19.

引用本文的文献

1
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations.针对甲型流感病毒基质蛋白2胞外域的非中和性抗体是广泛有效的治疗药物,且对病毒逃逸突变具有抗性。
Sci Adv. 2025 Sep 12;11(37):eadx3505. doi: 10.1126/sciadv.adx3505. Epub 2025 Sep 10.
2
Broad-Spectrum Antiviral Styrene Maleic-Acid Copolymer Lipid Particle Nanodiscs for pH-Responsive Irreversible Virus Inactivation.用于pH响应性不可逆病毒灭活的广谱抗病毒苯乙烯-马来酸共聚物脂质颗粒纳米盘
Biomacromolecules. 2025 Jul 14;26(7):4051-4068. doi: 10.1021/acs.biomac.5c00037. Epub 2025 Jun 10.
3
Immunoengineered adjuvants for universal vaccines against respiratory viruses.用于抗呼吸道病毒通用疫苗的免疫工程佐剂。
Fundam Res. 2021 Mar;1(2):189-192. doi: 10.1016/j.fmre.2021.01.010. Epub 2021 Jan 22.
4
Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses.潜在的广谱抗病毒药物:对抗新出现和再次出现的呼吸道RNA病毒的关键武器库。
Int J Mol Sci. 2025 Feb 10;26(4):1481. doi: 10.3390/ijms26041481.
5
How Broadly Neutralising Antibodies Are Redefining Immunity to Influenza.广泛中和抗体如何重新定义对流感的免疫力
Antibodies (Basel). 2025 Jan 7;14(1):4. doi: 10.3390/antib14010004.
6
Development of broadly protective influenza B vaccines.广谱保护性B型流感疫苗的研发。
NPJ Vaccines. 2025 Jan 7;10(1):2. doi: 10.1038/s41541-024-01058-w.
7
Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity.双特异性抗体同时中和流感病毒血凝素和神经氨酸酶可提高抗病毒活性。
Mol Ther. 2024 Oct 2;32(10):3712-3728. doi: 10.1016/j.ymthe.2024.07.023. Epub 2024 Jul 31.
8
Recent Advances, Approaches and Challenges in the Development of Universal Influenza Vaccines.通用流感疫苗研发的最新进展、方法和挑战。
Influenza Other Respir Viruses. 2024 Mar;18(3):e13276. doi: 10.1111/irv.13276.
9
Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes.鉴定和相对丰度的天然呈现和交叉反应的流感 A 病毒 MHC Ⅰ类限制性 T 细胞表位。
Emerg Microbes Infect. 2024 Dec;13(1):2306959. doi: 10.1080/22221751.2024.2306959. Epub 2024 Feb 8.
10
Mucosal correlates of protection after influenza viral challenge of vaccinated and unvaccinated healthy volunteers.接种疫苗和未接种疫苗的健康志愿者接种流感病毒后黏膜相关性保护。
mBio. 2024 Feb 14;15(2):e0237223. doi: 10.1128/mbio.02372-23. Epub 2024 Jan 9.

本文引用的文献

1
Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections.2009 年甲型 H1N1 流感病毒在志愿者人体挑战研究参与者和自然感染中的深度测序。
Virology. 2019 Aug;534:96-107. doi: 10.1016/j.virol.2019.06.004. Epub 2019 Jun 13.
2
Influenza Vaccines: Good, but We Can Do Better.流感疫苗:效果良好,但我们可以做得更好。
J Infect Dis. 2019 Apr 8;219(Suppl_1):S1-S4. doi: 10.1093/infdis/jiy633.
3
Making Universal Influenza Vaccines: Lessons From the 1918 Pandemic.研发通用流感疫苗:从 1918 年大流感中汲取的教训。
J Infect Dis. 2019 Apr 8;219(Suppl_1):S5-S13. doi: 10.1093/infdis/jiy728.
4
Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine.克服通用流感病毒疫苗道路上的障碍。
Cell Host Microbe. 2018 Jul 11;24(1):18-24. doi: 10.1016/j.chom.2018.06.016.
5
The influenza virus hemagglutinin head evolves faster than the stalk domain.流感病毒血凝素头部比茎部进化得更快。
Sci Rep. 2018 Jul 11;8(1):10432. doi: 10.1038/s41598-018-28706-1.
6
How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin.单突变如何影响 H1 流感血凝素对广谱和窄谱抗体的病毒逃逸。
Nat Commun. 2018 Apr 11;9(1):1386. doi: 10.1038/s41467-018-03665-3.
7
Antibody Immunodominance: The Key to Understanding Influenza Virus Antigenic Drift.抗体免疫显性:理解流感病毒抗原漂移的关键
Viral Immunol. 2018 Mar;31(2):142-149. doi: 10.1089/vim.2017.0129. Epub 2018 Jan 22.
8
Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain.H1 流感病毒血凝素茎结构域的自然定向抗原漂移。
Sci Rep. 2017 Nov 6;7(1):14614. doi: 10.1038/s41598-017-14931-7.
9
Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem.是否有可能开发出“通用”流感病毒疫苗?针对血凝素茎的泛亚型流感 A 疫苗开发中 B 细胞生物学的免疫遗传学考虑。
Cold Spring Harb Perspect Biol. 2018 Jul 2;10(7):a029413. doi: 10.1101/cshperspect.a029413.
10
A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus.免疫逃逸的结构和功能限制视角:来自流感病毒的见解
J Mol Biol. 2017 Aug 18;429(17):2694-2709. doi: 10.1016/j.jmb.2017.06.015. Epub 2017 Jun 23.

先前存在的对流感病毒血凝素茎的免疫可能会在人体挑战模型中推动对抗体逃逸突变病毒的选择。

Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.

机构信息

Viral Pathogenesis and Evolution Section, Laboratory of Infectious Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, USA.

出版信息

Nat Med. 2020 Aug;26(8):1240-1246. doi: 10.1038/s41591-020-0937-x. Epub 2020 Jun 29.

DOI:10.1038/s41591-020-0937-x
PMID:32601336
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7450362/
Abstract

The conserved region of influenza hemagglutinin (HA) stalk (or stem) has gained attention as a potent target for universal influenza vaccines. Although the HA stalk region is relatively well conserved, the evolutionarily dynamic nature of influenza viruses raises concerns about the possible emergence of viruses carrying stalk escape mutation(s) under sufficient immune pressure. Here we show that immune pressure on the HA stalk can lead to expansion of escape mutant viruses in study participants challenged with a 2009 H1N1 pandemic influenza virus inoculum containing an A388V polymorphism in the HA stalk (45% wild type and 55% mutant). High level of stalk antibody titers was associated with the selection of the mutant virus both in humans and in vitro. Although the mutant virus showed slightly decreased replication in mice, it was not observed in cell culture, ferrets or human challenge participants. The A388V mutation conferred resistance to some of the potent HA stalk broadly neutralizing monoclonal antibodies (bNAbs). Co-culture of wild-type and mutant viruses in the presence of either a bNAb or human serum resulted in rapid expansion of the mutant. These data shed light on a potential obstacle for the success of HA-stalk-targeting universal influenza vaccines-viral escape from vaccine-induced stalk immunity.

摘要

流感血凝素 (HA) 茎 (或干) 的保守区域作为通用流感疫苗的有效靶点引起了关注。尽管 HA 茎区相对保守,但流感病毒的进化动态性质引起了人们的担忧,即在足够的免疫压力下,携带茎逃逸突变的病毒可能会出现。在这里,我们表明,在研究参与者中,针对含有 HA 茎 A388V 多态性的 2009 年 H1N1 大流行流感病毒接种物的免疫压力可导致逃逸突变病毒的扩展(45%为野生型,55%为突变型)。在人类和体外实验中,高浓度的茎抗体滴度与突变病毒的选择有关。尽管突变病毒在小鼠中的复制能力略有下降,但在细胞培养、雪貂或人类挑战参与者中均未观察到。A388V 突变赋予了对一些有效的 HA 茎广泛中和单克隆抗体 (bNAb) 的抗性。在存在 bNAb 或人血清的情况下,将野生型和突变型病毒共培养会导致突变型病毒的快速扩展。这些数据揭示了 HA 茎靶向通用流感疫苗成功的一个潜在障碍——病毒逃避疫苗诱导的茎免疫。